Sector
PharmaceuticalsOpen
₹220.95Prev. Close
₹219.25Turnover(Lac.)
₹114.13Day's High
₹224.3Day's Low
₹21552 Week's High
₹26552 Week's Low
₹124.5Book Value
₹58.11Face Value
₹5Mkt Cap (₹ Cr.)
1,087.43P/E
19EPS
11.54Divi. Yield
1.14Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 25.06 | 25.06 | 25.06 | 25.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 266.16 | 216.17 | 188.72 | 165.59 |
Net Worth | 291.22 | 241.23 | 213.78 | 190.65 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 431.96 | 306.95 | 238.07 | 206.14 |
yoy growth (%) | 40.72 | 28.93 | 15.48 | -36.8 |
Raw materials | -329.79 | -230.16 | -180.79 | -150.61 |
As % of sales | 76.34 | 74.98 | 75.93 | 73.06 |
Employee costs | -14.29 | -13.36 | -9 | -7.21 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 38.55 | 19.15 | 23.41 | 27.58 |
Depreciation | -15.07 | -7.03 | -1.83 | -1.96 |
Tax paid | -10.11 | -4.85 | -6.9 | -7.53 |
Working capital | 61.47 | -22.96 | 11.14 | -7.43 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 40.72 | 28.93 | 15.48 | -36.8 |
Op profit growth | 95.81 | 27.2 | -18.66 | -40.08 |
EBIT growth | 100.75 | -14.96 | -15.1 | -27.25 |
Net profit growth | 98.78 | -13.36 | -17.64 | -22.29 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,864.95 | 159.18 | 4,43,025.21 | 237.82 | 0.73 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,481.5 | 86.91 | 1,44,368.45 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,657.1 | 33.1 | 1,31,446.53 | 1,055.94 | 0.8 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,459.8 | 77.39 | 1,16,311.7 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,120.15 | 25.62 | 1,11,913.34 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Vice Chairman
Bipin N Shah
Non-Exec & Non-Independent Dir
Bharat N Shah
Chairman (Non-Executive)
Arun L Todarwal
Non-Exec & Non-Independent Dir
Samir J Shah
Non-Exec & Non-Independent Dir
Ketan L Shah
Joint Managing Director
Ritesh B Shah
Joint Managing Director
Vivek B Shah
Non-Exec & Non-Independent Dir
Mita Dixit
Non-Exec. & Independent Dir.
Harmanbhai Tulsibhai Patel
Independent Director
Pradeep Thakur
Independent Director
Siddharth Shah
Non-Exec & Non-Independent Dir
Gaurav Shah
Company Sec. & Compli. Officer
Manan Jayesh Vadhan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Anuh Pharma Ltd
Summary
Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The Company is engaged in the business of manufacturing and selling of Bulk drugs and chemicals Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group.Anuh Pharma Ltd was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries.During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg.During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production.In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way f
Read More
The Anuh Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹217 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Anuh Pharma Ltd is ₹1087.43 Cr. as of 12 Sep ‘24
The PE and PB ratios of Anuh Pharma Ltd is 19 and 3.77 as of 12 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Anuh Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Anuh Pharma Ltd is ₹124.5 and ₹265 as of 12 Sep ‘24
Anuh Pharma Ltd's CAGR for 5 Years at 21.99%, 3 Years at 24.12%, 1 Year at 65.16%, 6 Month at 2.33%, 3 Month at -5.60% and 1 Month at 1.48%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice